Recent Updates
Recently added Catalysts
SMTI Positive Sentiment

Prevention of microbial biofilms on implantable materials in vitro with BIASURGE™ Advanced Surgical Solution

Thursday, April 11, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study evaluates the effectiveness of BIASURGE™ Advanced Surgical Solution in preventing microbial colonization and eradicating bacteria from various implantable materials. The research involved detailed in vitro studies that assessed both prevention and eradication methodologies. Findings indicate promising results for improving surgical outcomes.
Price reaction · baseline $33.17 (2024-04-11T15:59:00.000Z) · hit during market hours · clean, no other SMTI news in the window
day 0 close · peak
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful prevention of microbial colonization on implantable materials.
  • Effective eradication of bacteria from surfaces.
  • Innovative approach with BIASURGE™ Advanced Surgical Solution.

Full Press Release Details

Authors: Larry Estlack, Rebecca McMahon, PhD, Nina Bionda, PhD
This research study presents the results of a series of in vitro studies aimed at evaluating both prevention of microbial colonization of four different implantable materials, as well as eradication of bacteria already attached to the surface of these materials. The experimental methodology, considerations, and findings are discussed in detail below.

Frequently Asked Questions

What is the focus of the research study?

The study focuses on preventing microbial colonization and eradicating bacteria on implantable materials.

What methodology was used in the study?

The research involved a series of in vitro studies to evaluate the effectiveness of BIASURGE™.

What materials were tested in the study?

Four different implantable materials were evaluated for microbial colonization and bacteria eradication.

Who are the authors of the study?

The study was authored by Larry Estlack, Rebecca McMahon, PhD, and Nina Bionda, PhD.

ShareAdd on Google
Tags: SMTI Viatris Investor Conferences Healthcare BIASURGE microbial colonization implantable materials bacterial eradication in vitro studies
Last updated: Apr 11, 2024

Biotech snapshot

Cash runway
$29M liquidity · $0M/mo burn
Low dilution risk